Predict your next investment

SINOGENE company logo
HEALTHCARE | Biotechnology
sinogene.com.cn

See what CB Insights has to offer

Founded Year

2012

Stage

Series B | Alive

About SINOGENE

SINOGENE is an animal genetic science company based in China that focuses on gene testing, gene editing, cell therapy, animal cloning, and other services.

SINOGENE Headquarter Location

Building 310, 311, 312, Building 16, No. 37 Chaoqian Road Science and Technology Park, Changping District

Beijing, Beijing,

China

+86 010-89785957

Latest SINOGENE News

China Creates Transgenic Mice to Test COVID-19 Vaccine

Jul 10, 2020

China Creates Transgenic Mice to Test COVID-19 Vaccine https://sputniknews.com/science/202007101079848166-china-creates-transgenic-mice-to-test-covid-19-vaccine/ In late March, China kicked off the first phase of clinical trials to test the safety and effectiveness of its newly developed vaccine for the coronavirus. Chinese scientists have created coronavirus-resistant transgenic mice that can be used to test vaccines and drugs against COVID-19 , Mi Jidong, chief executive of the Beijing-based biotechnology company SinoGene, said on Friday. He explained that ordinary animals are immune to the corona, so using the methods of cloning and editing the genome makes it possible for scientists to transplant the human gene (hACE2) into genetically modified creatures. Mi said that this is done “in order to infect the animal participating in the experiment and test the effectiveness of vaccines or drugs”. According to him, the genetically engineered mice for testing a COVID-19 vaccine were created on 23 June as part of a joint project involving SinoGene, SPF Beijing Biotechnology, and several other companies. SinoGene, in turn, pointed out that "the use of hACE2 mice in relevant studies may significantly increase the effectiveness and success rate of preclinical drug testing”, including one pertaining to COVID-19. © REUTERS / Dado Ruvic The company also signalled a readiness to boost the process of making transgenic mice in order to support research work aimed at combating the coronavirus. Mi’s remarks come after China in June refuted accusations of being behind attempts to sabotage COVID-19 vaccine development in western countries, asking Rick Scott, a US senator who made such claims, to show proof. “Well, if he does have such evidence, just show it to us. No need to be shy", Chinese Foreign Ministry spokesperson Hua Chunying said, adding that vaccine development was not a race between China and the United States, "but one between mankind and the virus". The spokesperson recalled Chinese President Xi Jinping’s pledge that after being developed and deployed, China's COVID-19 vaccine “will be made a global public good”. “This will be China's contribution to enhancing vaccine accessibility and affordability in developing countries", Hua pointed out. Clinical trials of the first vaccine developed in China began in mid-March, with 108 volunteers taking part in the tests. The vaccine was developed by China's Academy of Military Medical Sciences in cooperation with the biotech firm CanSino Bio. The trials followed the World Health Organisation (WHO) declaring the COVID-19 outbreak a pandemic on 11 March after the disease, which originated in China's Wuhan last December, shifted to Europe and beyond. As of Thursday, there have been more than 11.8 million confirmed coronavirus cases worldwide, with more than 545,000 fatalities, according to the WHO’s latest estimates . ...

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SINOGENE

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SINOGENE is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.